🇺🇸 VRTX — Vertex Pharmaceuticals Incorporated
Salud CompraPrecio actual
549,04 USD
Máx. histórico
558,88
5 días
Split 2:1 del 24/08/2000
Caída desde máximo
-1,76%
Rango 52 semanas
406,67 – 568,67
Variación hoy
+3,44%
Cierre anterior
530,76
Rango de hoy
527,38 – 550,77
Volumen hoy
1.810.311
Peor caída histórica
-91,77%
02/11/2000 → 11/11/2003
Recuperado en 3885 días
Volatilidad anualizada ⓘ
54,63%
- Nombre completo
- Vertex Pharmaceuticals Incorporated
- Divisa
- USD
- Mercado
- NasdaqGS
- Sector
- Salud
- Industria
- Biotechnology
- Empleados
- 6.400
- PER ⓘ
- 36,82 (puede no estar actualizado)
- Dividend yield
- 0,00% (puede no estar actualizado)
- Precio objetivo analistas
- 578,71 USD (puede no estar actualizado)
- Primera cotización
- 24/07/1991
- Precio actualizado
- hace 14 horas
Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally. The company offers transformative medicines for people with serious diseases with a focus on specialty markets, such as cystic fibrosis (CF), sickle cell disease (SCD), transfusion dependent beta thalassemia (TDT), and acute pain. It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for people with CF 6 years of age and older; SYMDEKO/SYMKEVI for treatment of patients with CF 6 years of age and older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 month or older who have CF with ivacaftor. The company also develops CASGEVY for the treatment of SCD and TDT; JOURNAVX for the treatment of acute pain in adults; VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1/2 clinical trial; inaxaplin for the treatment of APOL1-mediated kidney disease, which is in single Phase 2 trial; VX-264 for treating Type 1 Diabetes; VX-670 for the treatment of myotonic dystrophy type 1; and VX-407, a small molecule corrector for the treatment of autosomal dominant polycystic kidney disease. In addition, the company also operates as a clinical-stage pharmaceutical company, that focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company sells its products primarily to specialty pharmacy and distributors, wholesalers, retail pharmacies, hospitals, and clinics. Vertex Pharmaceuticals Incorporated has a strategic collaboration with AbCellera Biologics Inc. to research, develop, manufacture, and commercialize multispecific T-cell engagers (TCEs) for autoimmune diseases and other conditions. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.
| Fecha | Ratio |
|---|---|
| 24/08/2000 | 2:1 |
| Fecha | Apertura | Máximo | Mínimo | Cierre | Variación | Volatilidad día | Volumen |
|---|---|---|---|---|---|---|---|
| 11/09/1998 | 9,44 | 9,44 | 9,00 | 9,19 | -2,65% | 4,64% | 485.400 |
| 10/09/1998 | 9,06 | 9,44 | 8,94 | 9,44 | +1,34% | 5,52% | 575.200 |
| 09/09/1998 | 9,88 | 9,88 | 9,25 | 9,31 | -6,29% | 6,33% | 490.600 |
| 08/09/1998 | 10,50 | 10,50 | 9,56 | 9,94 | -1,24% | 8,93% | 488.200 |
| 04/09/1998 | 9,13 | 10,16 | 9,00 | 10,06 | +13,98% | 12,67% | 450.600 |
| 03/09/1998 | 8,19 | 8,94 | 8,06 | 8,83 | +4,63% | 10,69% | 220.400 |
| 02/09/1998 | 8,25 | 8,50 | 7,97 | 8,44 | +2,27% | 6,44% | 501.200 |
| 01/09/1998 | 7,88 | 8,31 | 7,75 | 8,25 | +8,20% | 7,14% | 257.000 |
| 31/08/1998 | 8,06 | 8,06 | 7,25 | 7,63 | -5,43% | 10,08% | 602.600 |
| 28/08/1998 | 8,25 | 8,75 | 7,88 | 8,06 | -1,53% | 10,61% | 283.200 |
| 27/08/1998 | 7,69 | 8,31 | 7,50 | 8,19 | +3,35% | 10,57% | 379.400 |
| 26/08/1998 | 8,00 | 8,00 | 7,75 | 7,92 | -1,74% | 3,13% | 332.600 |
| 25/08/1998 | 8,44 | 8,50 | 8,06 | 8,06 | -1,53% | 5,19% | 420.200 |
| 24/08/1998 | 8,75 | 9,38 | 8,19 | 8,19 | -4,73% | 13,57% | 521.000 |
| 21/08/1998 | 8,28 | 8,59 | 7,44 | 8,59 | +1,85% | 13,96% | 581.400 |
| 20/08/1998 | 9,13 | 9,13 | 8,38 | 8,44 | -7,69% | 8,22% | 269.000 |
| 19/08/1998 | 9,38 | 9,38 | 9,03 | 9,14 | -2,82% | 3,67% | 308.400 |
| 18/08/1998 | 9,25 | 9,47 | 9,06 | 9,41 | +3,79% | 4,39% | 374.000 |
| 17/08/1998 | 9,56 | 9,56 | 9,03 | 9,06 | -6,45% | 5,56% | 407.000 |
| 14/08/1998 | 9,88 | 10,00 | 9,63 | 9,69 | -1,90% | 3,80% | 239.400 |
| 13/08/1998 | 10,22 | 10,25 | 9,88 | 9,88 | -3,95% | 3,67% | 168.800 |
| 12/08/1998 | 10,31 | 10,38 | 10,22 | 10,28 | +0,92% | 1,51% | 190.200 |
| 11/08/1998 | 10,50 | 10,75 | 10,16 | 10,19 | -7,39% | 5,65% | 840.200 |
| 10/08/1998 | 10,63 | 11,00 | 10,44 | 11,00 | +4,14% | 5,29% | 174.800 |
| 07/08/1998 | 10,13 | 10,88 | 10,13 | 10,56 | +3,05% | 7,41% | 427.800 |
| 06/08/1998 | 9,63 | 10,25 | 9,50 | 10,25 | +4,79% | 7,79% | 104.200 |
| 05/08/1998 | 9,63 | 9,88 | 9,44 | 9,78 | +1,29% | 4,55% | 258.600 |
| 04/08/1998 | 10,50 | 10,56 | 9,59 | 9,66 | -6,36% | 9,23% | 687.000 |
| 03/08/1998 | 10,50 | 10,50 | 10,25 | 10,31 | -1,20% | 2,38% | 119.400 |
| 31/07/1998 | 10,44 | 10,69 | 10,38 | 10,44 | -0,89% | 2,99% | 323.600 |